文献速递产科母胎医学

慢性高血压女性孕早期血清血管生成与抗血管生成因子预测子痫前期

First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2019-11-06

本研究纳入650例慢性高血压孕妇(其中202例发生重叠性子痫前期、448例未发生)和142例血压正常对照,检测孕11+0至13+6周血清胎盘生长因子(PlGF)与可溶性fms样酪氨酸激酶-1(sFlt-1)浓度。发生重叠性子痫前期者孕早期PlGF与sFlt-1中位数均显著低于未发生者,且两者均低于血压正常对照;但两指标对重叠性子痫前期的预测能力较差。

要点

  • 慢性高血压孕妇中,后续发生重叠性子痫前期者孕早期血清PlGF和sFlt-1中位数均显著低于未发生者。
  • 发生与未发生重叠性子痫前期的慢性高血压孕妇,其PlGF和sFlt-1均低于血压正常对照。
  • 三组间sFlt-1/PlGF比值无显著差异,两指标对重叠性子痫前期预测能力较差。

核心结论

  • 慢性高血压女性,尤其是后续发生子痫前期者,孕早期PlGF和sFlt-1浓度均降低。

研究设计与样本

  • 研究纳入650例慢性高血压女性(202例发生重叠性子痫前期、448例未发生子痫前期)和142例血压正常对照。
  • 采用自动化生化分析仪测定孕11+0至13+6周母体血清PlGF和sFlt-1浓度,并以多变量回归分析在对照组中转换为期望中位数倍数。
  • 采用方差分析或Kruskal-Wallis检验比较慢性高血压两组与对照组的PlGF、sFlt-1及sFlt-1/PlGF比值。

主要发现

  • 发生重叠性子痫前期的慢性高血压女性血清PlGF期望中位数倍数的中位数为0.904(四分位距0.771-1.052),未发生者为0.948(四分位距0.814-1.093),P=.014。
  • 发生重叠性子痫前期的慢性高血压女性血清sFlt-1期望中位数倍数的中位数为0.895(四分位距0.760-1.033),未发生者为0.938(四分位距0.807-1.095),P=.013。
  • 发生重叠性子痫前期者PlGF和sFlt-1均低于血压正常对照(分别为1.009[四分位距0.901-1.111]和0.991[四分位距0.861-1.159]),两者P均<.01。
  • 三组间sFlt-1/PlGF比值无显著差异。
  • 在慢性高血压女性中,血清PlGF和sFlt-1对重叠性子痫前期的预测能力较差,曲线下面积分别为0.567(95%置信区间0.537-0.615)和0.546(95%置信区间0.507-0.585)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An imbalance between angiogenic and antiangiogenic factors is thought to be a central pathogenetic mechanism in preeclampsia. In pregnancies that subsequently experience preeclampsia, the maternal serum concentration of the angiogenic placental growth factor is decreased from as early as the first trimester of pregnancy, and the concentration of the antiangiogenic soluble fms-like tyrosine kinase-1 is increased in the last few weeks before the clinical presentation of the disease. Chronic hypertension, which complicates 1-2% of pregnancies, is the highest risk factor for the development of preeclampsia among all other factors in maternal demographic characteristics and medical history. Two previous studies in women with chronic hypertension reported that first-trimester serum placental growth factor and soluble fms-like tyrosine kinase-1 levels were not significantly different between those who experienced superimposed preeclampsia and those who did not, whereas a third study reported that concentrations of placental growth factor were decreased. OBJECTIVE: The purpose of this study was to investigate whether, in women with chronic hypertension, serum concentrations of placental growth factor and soluble fms-like tyrosine kinase-1 and soluble fms-like tyrosine kinase-1/placental growth factor ratio at 11+0-13+6 weeks gestation are different between those women who experienced superimposed preeclampsia and those who did not and to compare these values with those in normotensive control subjects. STUDY DESIGN: The study population comprised 650 women with chronic hypertension, which included 202 women who experienced superimposed preeclampsia and 448 women who did not experience preeclampsia, and 142 normotensive control subjects. Maternal serum concentration of placental growth factor and soluble fms-like tyrosine kinase-1 were measured by an automated biochemical analyzer and converted into multiples of the expected median with the use of multivariate regression analysis in the control group. Comparisons of placental growth factor and soluble fms-like tyrosine kinase-1 levels and soluble fms-like tyrosine kinase-1/placental growth factor ratio in multiples of the expected median values between the 2 groups of chronic hypertension and the control subjects were made with the analysis of variance or the Kruskal-Wallis test. RESULTS: In the group of women with chronic hypertension who experienced preeclampsia compared with those women who did not experience preeclampsia, there were significantly lower median concentrations of serum placental growth factor multiples of the expected median (0.904 [interquartile range, 0.771-1.052] vs 0.948 [interquartile range, 0.814-1.093]; P=.014) and soluble fms-like tyrosine kinase-1 multiples of the expected median (0.895 [interquartile range, 0.760-1.033] vs 0.938 [interquartile range, 0.807-1.095]; P=.013); they were both lower than in the normotensive control subjects (1.009 [interquartile range, 0.901-1.111] and 0.991 [interquartile range, 0.861-1.159], respectively; P<.01 for both). There were no significant differences among the 3 groups in soluble fms-like tyrosine kinase-1/placental growth factor ratios. In women with chronic hypertension, serum placental growth factor and soluble fms-like tyrosine kinase-1 levels provided poor prediction of superimposed preeclampsia (area under the curve, 0.567 [95% confidence interval, 0.537-0.615] and 0.546 [95% confidence interval, 0.507-0.585], respectively). CONCLUSION: Women with chronic hypertension, and particularly those who subsequently experienced preeclampsia, have reduced first-trimester concentrations of both placental growth factor and soluble fms-like tyrosine kinase-1.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Nzelu D, Biris D, Karampitsakos T, et al. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia. Am J Obstet Gynecol. 2019. PMID: 31705883. doi:10.1016/j.ajog.2019.10.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。